Nurix Therapeutics, Inc. (NRIX) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 1:30 PM EDT
Company Participants
Arthur Sands – CEO, President & Director
Jason Kantor – Chief Business Officer
Conference Call Participants
Brian Abrahams – RBC Capital Markets, Research Division
Presentation
Brian Abrahams
RBC Capital Markets, Research Division
So let’s get started. Good afternoon, everyone. Welcome back from lunch. I’m Brian Abrahams, senior biotech analyst here at RBC Capital Markets. We’re really pleased to have our next featured company, Nurix Therapeutics, represented by their CEO, Arthur Sands and their CBO, Jason Kantor.
Arthur Sands
CEO, President & Director
Great. Good to be here. Thanks, Brian.
Question-and-Answer Session
Brian Abrahams
RBC Capital Markets, Research Division
Thanks for being here. So maybe let’s start a little bit bigger picture on your lead program, Bexdeg. Tell us what your latest view is on the potential advantages that BTK degraders can have in the CLL space relative to the currently available inhibitors, what’s out there today? And what’s been your view as to the strongest preclinical and clinical evidence and data to date that’s really helped support that? And I know the data is continuing to evolve. So I would love to hear your latest views on that.
Arthur Sands
CEO, President & Director
Yes, excellent question. The advantage of targeted protein degrader in this space in CLL and in BTK, we’re seeing advantages expand and grow. So I can tell you where we started and now where we think it is, which is quite exciting.
So we started with the concept that by removing the protein, we could address certain BTK inhibitor resistance mutations, which were just emerging, if you go back to the beginning of, let’s say, 2020, 2019. So the concept that by degrading the protein through the ubiquitous proteasome system, we could address this emerging problem
You must be logged in to post a comment Login